Gallant 募集18M元用于发展宠物干细胞疗法, Gallant raises $18M to develop stem cell therapies for pets, targeting diseases like feline gingivostomatitis.

Gallant是一家动物健康生物技术公司,获得1 800万美元的资金,用于为宠物研制现成使用的干细胞疗法。 Gallant, an animal health biotech firm, secured $18 million in funding to develop ready-to-use stem cell therapies for pets. 在Digitalis Ventures的带领下,这项投资将加快林业发展局的核准程序,以治疗Feline Central Gingivostomatitis,并支持对狗和猫的其他常见疾病的治疗。 Led by Digitalis Ventures, this investment will speed up the FDA approval process for their treatment of Feline Chronic Gingivostomatitis and support therapies for other common diseases in dogs and cats. 这标志着兽医护理的新时代,针对这些病症的根本原因。 This marks a new era in veterinary care by targeting the root causes of these conditions.